Huntington's disease is a rare, inherited neurological disorder that affects individuals at the peak of their lives, causing permanent damage to brain cells and progressively affecting movement, cognitive functions, and behavior. It is an incapacitating disorder without cure, although its genetic cause has been identified for many decades, scientists have been struggling with the mechanism by which it manifests in people carrying the mutation since birth but remains symptom-free until adulthood.

Recent studies have unveiled how Huntington's disease is triggered. They explain the mechanism by which an apparently latent genetic mutation becomes a killer.

Huntington's disease is essentially caused by a genetic mutation in the HTT gene, which codes for a protein called huntingtin. The mutation consists of the abnormal repetition of a three-letter DNA sequence, CAG, within the gene.

In healthy individuals, the CAG sequence is repeated 15 to 35 times. People with Huntington's disease have more than 40 repeats. This excess leads to the production of a defective huntingtin protein that becomes toxic over time.

But here’s the twist: this mutation doesn’t wreak havoc immediately. For years, even decades, it remains relatively harmless. Scientists have now discovered that the mutation grows progressively, expanding the number of CAG repeats over time. When the count surpasses a critical threshold—about 150 repeats—certain neurons become overwhelmed, triggering cell death and the onset of symptoms.

How the Mutation Grows Over Time and Cause Brain Damage?

Breakthrough research done by scientists from the Broad Institute of MIT and Harvard, McLean Hospital, and Harvard Medical School has mapped out the expansion of this mutation in exquisite detail. Analyzing the brain tissue from those with and without Huntington's disease, they discovered how the mutation evolves.

Slow Start

For the first two decades of life, DNA repeats expand slowly and do not pose an immediate threat.

Fast Forward

At about the 80-CAG mark, expansion increases its pace and then it starts the chain reaction of toxic effects.

Critical Point

Above 150 or more repeats the mutation causes the neurons to start sickness and eventually die, giving the hallmark symptoms of Huntington's disease.

According to co-senior author Dr. Steve McCarroll, these results are "surprising," in that they showed a direct relationship between the size of the repeats and the age at which the disease began. In fact, it has been greeted with skepticism within the scientific community, as prior studies had suggested that smaller expansions were enough to cause the disease. However, new information debunks that any expansions under 100 CAGs may involve a higher risk but does not drive the full onset of Huntington's.

What is Huntington's disease?

Huntington's disease is a genetic disorder that progressively leads to the death of brain cells. It primarily affects regions of the brain responsible for voluntary movement and memory. Individuals with Huntington's often experience symptoms such as uncontrollable movements, along with significant changes in thinking, behavior, and personality. Over time, these symptoms progressively worsen, severely impacting quality of life.

Symptoms of Huntington's disease

Symptoms of Huntington's disease appear between the ages of 30 and 50 and worsen gradually over a period of 10 to 25 years. The disease affects physical and mental functions, causing: Involuntary movements (chorea)

• unsteady gait
• poor coordination
• Difficulty concentrating
• memory loss
• poor judgment
• Irritability
• depression
• personality changes
• eventual loss of independence

The severity of these symptoms impairs the quality of life for a person and his or her family, thus placing a premium on finding effective treatments.

What Does This Mean for Huntington's disease Treatment

While a broadening understanding of Huntington's disease, the current treatments available are essentially symptomatic. The drugs are capable of alleviating any movement disorders and mood alterations but don't alter the process of the disease progression.

Experimental drugs aimed at reducing the amounts of toxic proteins have had little success in human trials, mainly because at any one time, only relatively few cells express the poisonous version of the huntingtin protein. But a new study holds out a potential hope, the possibility of intervening before a DNA repeat becomes pathogenic.

Dr. McCarroll and his team believe that slowing or stopping the expansion of CAG repeats could delay or even prevent the onset of Huntington's disease. Although this approach remains experimental, it has already spurred renewed interest among pharmaceutical companies to develop therapies aimed at stabilizing the mutation.

About 41,000 Americans currently live with the disease, though tens of thousands more are expected to be afflicted because Huntington's is a genetic disorder. Discoveries such as these provide an inkling of hope for affected families, uncertain about their situations.

While there is no guarantee that stopping the expansion of CAG repeats will cure Huntington's, this research is a significant step toward understanding the disease at its molecular level. Scientists are optimistic that these findings could pave the way for preventive treatments that protect vulnerable neurons from succumbing to the toxic effects of the mutation.

As Dr. Sabina Berretta, a senior author of the study, noted, "The longer the repeats, the earlier in life the onset will happen." Armed with this knowledge, researchers are now better equipped to explore interventions that could delay the devastating symptoms of Huntington's disease and, perhaps, one day prevent them entirely.

Huntington's disease remains one of the major challenges; however, scientific research has given tremendous insights into what the real roots of the condition are. Thus, researchers open new doors toward treatments that might change the path of this devastative condition with the knowledge about how the mutation evolves and comes to a tipping point.

Long somatic DNA-repeat expansion drives neurodegeneration in Huntington’s disease. Cell. 2025

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993

At just 14 years old, Siddharth Nandyala is already changing the face of modern medicine. A native of Anantapur in Andhra Pradesh in India, living in Frisco, Texas, this young genius is causing global waves with the development of CircadiaV, a revolutionary AI-powered mobile app that can diagnose heart disease within a record seven seconds. With nothing more than a smartphone and sophisticated machine learning, Siddharth's invention has the potential to transform cardiovascular disease screening—one of the globe's top causes of death.

With certification from international tech giants such as Oracle and ARM, Siddharth is officially the world's youngest AI-certified professional but behind the titles and accolades, it's his vision for affordable, early healthcare interventions that really sets him apart. While most teenagers are at the age playing around with social media and video games, Siddharth is addressing medical challenges on a global scale.

Heart disease remains the primary cause of death in the world, resulting in more than 17.9 million deaths annually, as reported by the World Health Organization (WHO). A significant portion of those deaths are avoidable if diagnosed early enough. Unfortunately, the absence of medical diagnostic infrastructure in remote and underprivileged regions—particularly in developing nations—is an enormous challenge.

How CircadiaV Works?

What sets CircadiaV apart is its non-invasive, fast, and precise method for early detection of heart disease. The app can capture heart sounds by holding a smartphone against a patient's chest. It removes ambient noise, analyzes the audio data through a cloud-based machine learning model, and provides results in seven seconds.

The program can identify various cardiac anomalies, such as:

• Arrhythmias (irregular heartbeats)
• Early indications of heart failure
• Indicators of coronary artery disease
• Abnormalities in the heart valves

And it's amazingly precise—with a detection accuracy of more than 96%, as confirmed through testing on over 15,000 patients in America and another 700 in India, including at the Guntur Government General Hospital (GGH).

This application does not substitute for the EKG but is used as a quick, scalable pre-screen," Siddharth said to the Smithsonian Magazine. That clarification is important—it is not intended for consumer use at home or consumer diagnostics, but is designed to assist medical personnel, especially in impoverished environments where full cardiac diagnostics might not be within reach.

That is where CircadiaV comes in. Its low-cost, cloud-based, and portable nature makes it a perfect device for community clinics and frontline health workers. The application can be utilized in rural areas to give an early diagnosis, leading to early referrals and possibly cutting long-term morbidity and mortality.

An initial potential diagnosis in patients otherwise unlikely to have had access to medical treatment may in the end save long-term morbidity and mortality from this disease.

That is, this app could literally be a lifesaver—particularly for patients in rural towns, refugee camps, or even wartime zones where cardiologists and expensive diagnostic technology are scarce.

More Than Just a One-Time Invention

Siddharth's foray into innovation had not begun with CircadiaV. Prior to this, he had created a low-cost prosthetic arm, a innovation to enhance mobility for individuals with limb loss in underprivileged communities. He also had started STEM IT, a company that creates science and technology kits for children, enabling experiential STEM learning across socioeconomic barriers.

His success has already seen him receive national and international acclaim, including a Certificate of Recognition from the US House of Representatives and a congratulatory letter from President Joe Biden.

And although he is as old as some of his classmates are young, Siddharth has just become a computer science major at the University of Texas. And his goals don't end there. He hopes to make CircadiaV capable of not just detecting lung diseases like pneumonia and pulmonary embolism, but also of analyzing recordings of lung sounds just like the app presently analyzes heart sound recordings.

Clinically, prompt detection is the key to success with cardiovascular treatment. Most terminal cardiac illnesses—such as congestive heart failure or severe coronary artery disease—are salvageable if detected early. But when symptoms intensify, choices narrow, and survival rates plummet.

By providing healthcare professionals with an advantage with CircadiaV, Siddharth is delivering:

• Earlier detection = quicker decision-making on treatment
• Non-invasive screening guarantees greater uptake in community-based screening
• Cloud-fueled insights enable real-time collaboration among rural clinics and urban hospitals

Consider the following: a community health worker in a remote village in India uses a smartphone to identify early-stage heart failure in a 55-year-old man. Rather than waiting weeks for a cardiology visit, that patient can be expedited for further testing and treatment—saving his life.

The app is particularly useful for terminal heart patients whose survival chances raise significantly if the condition is detected at the asymptomatic or initial phases. With correct warnings regarding the development of arrhythmias or valve malfunctions, the technology enables physicians to act before it is too late.

India's Covid-19 trajectory has taken a sharp upward turn since the end of May, sparking fears of a potential new wave of infections. The active Covid-19 cases rose to 6,815 as of June 11—considerably higher than only 257 cases on May 22—according to the Union Ministry of Health dashboard.

Over the last 24 hours alone, the nation logged 324 fresh cases, accompanied by 783 recoveries and three new virus-linked deaths. This increase, while not yet a major outbreak by any means, indicates a change that will be monitored—specifically because states such as Kerala, Gujarat, and Karnataka are registering a steady rise.

Public health agencies have cautioned that although the severity of infections as a whole is still under control because of high inoculation levels and hybrid immunity, susceptible groups, particularly the elderly and those who suffer from co-morbidities, are still under substantial risk of developing complications or dying.

Three further Covid-related deaths were reported on June 10, taking India's death toll in 2025 to 68. These comprised:

A 90-year-old female in Delhi with co-morbidities such as Congestive Heart Failure (CCF), Chronic Kidney Disease (CKD), and respiratory acidosis.

A 79-year-old male in Kerala, who was controlling Type 2 diabetes and other chronic diseases.

A 44-year-old male in Jharkhand, who had severe multiple conditions such as aspirational pneumonia, acute respiratory distress syndrome (ARDS), septic shock, hypertension, and hypothyroidism.

These examples highlight a stern reality: even with advances in medical interventions, Covid-19 is risky—particularly for individuals with compromised immune systems or existing health issues.

Kerala has the highest active caseload currently, with 2,053 active infections and 96 fresh cases in the past 24 hours. Even with its strong healthcare setup and high awareness rate, the state continues to fight against the virus due to its ageing population and lifestyle disease prevalence.

Gujarat is next, with 1,109 active cases, with Surat alone having 166. Karnataka, which logged 136 new cases in 24 hours, is another hotbed, reporting two deaths in the past 24 hours.

Incidentally, Delhi, having reported one death, registered a drop in active cases—691 now. Experts attribute this to timely public health interventions and increasing immunity in cities.

Why Are Hospital Admissions Being Led by High-Risk Patients?

Although the majority of new infections have been asymptomatic or mild, hospitalizations are disproportionately accounted for by high-risk groups, such as the elderly and those with underlying health conditions.

Recent fatalities in Delhi and Jharkhand included patients who were either old or had concurrent chronic diseases. According to medical professionals, these patients have lesser ability to develop an adequate immune response, and therefore they are prone to develop complications such as sepsis, respiratory failure, or multi-organ dysfunction if they contract Covid-19.

To an international audience, India's current Covid-19 data are not mere figures—what they show is a dynamic, living picture of how the pandemic is being addressed in one of the world's most populated countries.

The rebound is a warning for other nations that have reduced Covid-19 monitoring. The combination of declining immunity, viral evolution, and underreporting may easily spur new waves in other parts of the world, particularly as travel expands and public complacency deepens.

India's widespread Covid-19 surveillance system presents early notice of the potential for new variants and geographic trends. A spike here may, in the past, herald a ripple effect worldwide—as was the case with previous waves.

Why Are Individuals with Co-Morbidities Experiencing the Worst Outcomes?

The link between co-morbidities and worse Covid-19 outcomes has been clear from the beginning of the pandemic. Diseases such as diabetes, heart disease, kidney issues, obesity, and weakened immune systems severely limit the body's capacity to resist infection. Here's why:

Impaired Immune Function: Chronic diseases weaken the immune system's capability to detect and fight new infections efficiently.

Elevated Inflammatory Biomarkers: Underlying diseases tend to raise baseline levels of inflammation within the body, which in the event of a Covid-19 infection can spiral out of control into cytokine storms and serious systemic complications.

Delayed Hospitalization or Diagnosis: Most at-risk patients avoid care because of overlapping symptoms or ignorance, resulting in late disease at presentation.

Drug Interactions and Treatment Limits: Many patients with chronic diseases are already on medication regimens that can complicate Covid treatment, limiting options for antiviral therapies or supportive interventions.

The elderly and those with multiple diseases often experience rapid progression from mild symptoms to severe respiratory distress or organ failure. Vigilant monitoring and early intervention are critical in such cases.

Is a New COVID-19 Wave Here?

While India is witnessing a sharp rise in Covid-19 cases—jumping from just 257 active cases on May 22 to nearly 7,000 by June 11—experts are cautious about declaring it a full-blown new wave. The current surge appears localized, with states like Kerala, Gujarat, and Karnataka leading the spike. Most cases remain mild, and hospitalizations are limited to high-risk individuals with co-morbidities. Health officials are tracking for emerging variants closely but have not yet spotted any concerning mutations. Although it is not a new wave, the trend points to calls for increased vigilance, in particular for the elderly and the immunocompromised.

Indian health officials are calling for continued wearing of masks in risk areas, booster doses of vaccination, and early reporting of symptoms—particularly among vulnerable groups.

A few state health departments are stepping up genome sequencing and contact tracing in order to eliminate the possibility of any new sub-variants that could be fuelling this upsurge. There is no official confirmation on a new variant yet, but researchers are keeping a lookout.

The Union Health Ministry is also urging enhanced hospital readiness, reconsidering oxygen and ventilator inventories, and releasing advisories to local governments to stay vigilant.

The mpox outbreak continues to be a public health emergency, the World Health Organization (WHO) announced on Monday. The agency’s director-general also issued an updated set of temporary recommendations.

WHO had first declared the emergency in August last year, after a new strain of mpox spread from the severely affected Democratic Republic of Congo to nearby countries.

A public health emergency of international concern remains WHO’s highest level of alert.

What Is Mpox?

Mpox or monkey-pox is a viral disease in Africa. This was discovered by captive monkeys in 1958, after whom the disease was named in 1970. However, the name was later changed as it attracted many racist comments, especially on social media, where people wrote “the disease of monkeys” and associated it with the African people.

However, under the WHO guidelines, the naming of diseases must not drive any unnecessary negative impact on trade, travel, tourism or animal welfare, and avoid offending any cultural, social, national, regional, professional or ethnic groups. Thus, the name monkey-pox became the ‘m-pox’.

The outbreak led to WHO to declare an international public health emergency (PHEIC), from July 2022 to May 2023 in Congo. Now a new strain of the m-pox is infecting people in Kenya and poses a threat to many other African countries, including Congo.

How to detect it?

There are signs and symptoms of M-pox. They start to show within seven to 14 days of being infected. Therefore, for about a week a person may not know they have m-pox, and they can spread it by travelling.

The earliest signs are getting a fever, sweating and having chills through your body.

Other signs involve rashes, which start from a distant rash on the face and spread throughout the body. These rashes can be in different forms, sometimes a flat lesion, bumps, boils or scabs.

Other symptoms include swollen lymph nodes, migraine, muscle aches, fatigue, weakness and back pain.

How to prevent it?

This is a contagious infection and can spread by skin-to-skin contact. There are certain ways to prevent the spread. The first one is restricting your movement. Avoid going out in public, meeting people and interacting with animals.

Wear clothes that will prevent skin-to-skin infections. Cover yourself well so you do not spread the infection from your skin to other people.

Though there is no vaccination for the disease, doctors have noted that smallpox vaccination works on it to some extent.

Other ways are to keep hydrating yourself to get rid of the toxins from your body.

Doctors also prescribe medications like acetaminophen and ibuprofen to treat the pain and fever one may experience after being infected. Antiviral treatment like tecovirimat has been said to work on the infection too.